Vicapsys Life Sciences, Inc. (VICP)
1.50
0.00 (0.00%)
USD |
OTCM |
Feb 23, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 48.56M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -26.83% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 100.0% |
Profile
| Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. Its product name VICAPSYN is the firm's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The firm's lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company was founded on December 26, 1996 and is headquartered in Suwanee, GA. |
| URL | http://vicapsys.com |
| Investor Relations URL | N/A |
| HQ State/Province | Georgia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. Its product name VICAPSYN is the firm's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The firm's lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company was founded on December 26, 1996 and is headquartered in Suwanee, GA. |
| URL | http://vicapsys.com |
| Investor Relations URL | N/A |
| HQ State/Province | Georgia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |